Bain Capital Life Sciences Investors’s InflaRx IFRX Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio IFRX Stock Details IFRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-732,670	Closed	-$27.7M	–	6
2019 Q1	$27.7M	Sell	732,670 -1,032,218	-58%	-$38.5M	11.07%	3
2018 Q4	$64.2M	Hold	1,764,888	–	–	21.93%	2
2018 Q3	$60.6M	Sell	1,764,888 -1,150	-0.1%	-$37.1K	13.75%	4
2018 Q2	$57M	Sell	1,766,038 -110,375	-6%	-$3.81M	17.85%	3
2018 Q1	$54.1M	Hold	1,876,413	–	–	31.91%	2
2017 Q4	$39.3M	Buy	+1,876,413	New	+$33.9M	25.79%	2

Other funds holding IFRX

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Leap Investments Chicago, Illinois $152M AUM 3.6% 1-Year Est. Return

Bain Capital Life Sciences Investors's IFRX Position: Q2 2019 in Review

Bain Capital Life Sciences Investors sold out of InflaRx (IFRX) in Q2 2019, closing a stake of 732,670 shares — an estimated $27.7M sold.

Bain Capital Life Sciences Investors first reported a position in IFRX in Q4 2017 and held it in 6 quarters. The position peaked at $64.2M in Q4 2018. 28 funds tracked by Wall St. Rank hold IFRX as of Q2 2019.

Bain Capital Life Sciences Investors reported no remaining InflaRx position as of Q2 2019 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 732,670 InflaRx shares in Q2 2019, an estimated $27.7M.
Bain Capital Life Sciences Investors first reported a position in InflaRx in Q4 2017 and held it in 6 quarters.
Bain Capital Life Sciences Investors's InflaRx position peaked at $64.2M in Q4 2018.
28 funds tracked by Wall St. Rank held InflaRx as of Q2 2019.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2019, filed 14 Aug 2019.